News & Videos - PARAGON 28 INC. - English

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons (“AAOS”). From March 10 th – 14 th , Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8 million, representing reported growth of approximately 18.0% to 18.5% compared to the fourth quarter of...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Chadi Chahine, CFO & EVP of Supply Chain Operations, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the...

Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its...

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSE: FNA) and reminds investors of the November 29, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Chadi Chahine, CFO, will participate in a fireside chat at the 36 th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company’s...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE: FNA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Paragon filed an 8-K with the SEC on July 30, 2024. The filing stated, "On July 30, 2024, the Audit Committee...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE: FNA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Paragon filed an 8-K with the SEC on July 30, 2024. The filing stated, "On July 30, 2024, the Audit Committee...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance. Second Quarter 2023 and Six Months Ended June 30, 2023 Financial Results Consolidated net revenue for the second quarter of 2023 was $51.0 million, representing 20.0% and 20.8% reported and constant currency growth,...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company’s...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (888-330-2446) for domestic...

Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy (SMO) Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies. The system includes patent pending drilling and cutting guides to facilitate repeatable and controlled anterior dome, medial opening, and closing wedge osteotomies. The system also includes a patent pending allograft...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance. First Quarter 2023 Financial Results Consolidated net revenue for the first quarter of 2023 was a record $52.0 million, representing 25.8% and 27.1% reported and constant currency growth, respectively, over the first quarter...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 5:20 p.m. Eastern Time / 3:20 p.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the...

Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of the lesser metatarsals. These osteotomies are preformed to prevent metatarsalgia and floating toe, two of the most frequently addressed foot and ankle pathologies. The system includes a patent pending cut guide allowing for increased precision when performing the correction. This press...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2022. Fourth Quarter and Full Year 2022 Financial Results Consolidated net revenue for the fourth quarter of 2022 was $51.5 million, representing 20.4% and 22.1% reported and constant currency growth, respectively. Consolidated net revenue for the full year 2022 was $181.4 million,...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will be presenting in fireside chats at two upcoming investor conferences. Paragon 28 will participate in the CG 2023 Musculoskeletal Conference on March 7 th , 2023, and the 22 nd Annual Needham Virtual Healthcare Conference on April 19 th , 2023. Event: CG 2023 Musculoskeletal Conference Date:...